Status:
COMPLETED
Plerixafor for Stem Cell Mobilization in Normal Donors
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborating Sponsors:
Proteonomix, Inc.
Conditions:
Blood And Marrow Transplantation
Eligibility:
All Genders
10+ years
Phase:
PHASE2
Brief Summary
The goal of this clinical research study is to learn if treating stem cell donors with filgrastim (G-CSF) and plerixafor (Mozobil®) can cause them to produce a higher number of blood stem cells than f...
Detailed Description
Stem Cell Transplant: You will receive blood stem cells from a donor on this study. You will sign a separate informed consent for the transplant procedure. Follow-Up Visits: About 1, 3, and 6 month...
Eligibility Criteria
Inclusion
- Donor eligibility: Age \>/= 10 years.
- Donor eligibility: Related donors who met standard eligibility criteria and are willing to participate in this study.
- Donor eligibility: Able to provide informed consent.
- Recipient Eligibility: Patients who are scheduled to undergo an allogeneic related transplant and whose donors consented to participate in this study.
- Recipient Eligibility: Able to provide informed consent.
Exclusion
- 1\) Donors who are on anti-coagulation or anti-platelet agents are not eligible.
Key Trial Info
Start Date :
October 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2016
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT01818284
Start Date
October 1 2013
End Date
June 1 2016
Last Update
April 23 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030